KR20200095472A - 조산아에서의 점막 방어 및 장/폐 기능의 성숙화 - Google Patents

조산아에서의 점막 방어 및 장/폐 기능의 성숙화 Download PDF

Info

Publication number
KR20200095472A
KR20200095472A KR1020207015411A KR20207015411A KR20200095472A KR 20200095472 A KR20200095472 A KR 20200095472A KR 1020207015411 A KR1020207015411 A KR 1020207015411A KR 20207015411 A KR20207015411 A KR 20207015411A KR 20200095472 A KR20200095472 A KR 20200095472A
Authority
KR
South Korea
Prior art keywords
defensin
hbd
mammalian
lactoferrin
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207015411A
Other languages
English (en)
Korean (ko)
Inventor
피터 노드킬드
Original Assignee
디펜신 테라퓨틱스 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디펜신 테라퓨틱스 에이피에스 filed Critical 디펜신 테라퓨틱스 에이피에스
Publication of KR20200095472A publication Critical patent/KR20200095472A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207015411A 2017-11-10 2018-11-09 조산아에서의 점막 방어 및 장/폐 기능의 성숙화 Ceased KR20200095472A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17201002 2017-11-10
EP17201002.7 2017-11-10
PCT/EP2018/080814 WO2019092201A2 (en) 2017-11-10 2018-11-09 Maturation of mucosal defense and gut/lung function in the preterm infant

Publications (1)

Publication Number Publication Date
KR20200095472A true KR20200095472A (ko) 2020-08-10

Family

ID=60301879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015411A Ceased KR20200095472A (ko) 2017-11-10 2018-11-09 조산아에서의 점막 방어 및 장/폐 기능의 성숙화

Country Status (13)

Country Link
US (2) US20200316172A1 (https=)
EP (1) EP3706773A2 (https=)
JP (1) JP2021502363A (https=)
KR (1) KR20200095472A (https=)
CN (1) CN111556759A (https=)
AU (1) AU2018363783A1 (https=)
BR (1) BR112020009254A2 (https=)
CA (1) CA3082288A1 (https=)
MX (1) MX2020004863A (https=)
RU (1) RU2020115758A (https=)
SG (1) SG11202003868UA (https=)
WO (1) WO2019092201A2 (https=)
ZA (1) ZA202002992B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240150943A (ko) 2023-04-10 2024-10-17 (주)인트젠 영유아용 유산균 프로바이오틱스 조성물

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019006848A (es) * 2016-12-13 2019-10-07 Defensin Therapeutics Aps Metodos para tratar condiciones inflamatorias de los pulmones.
PL3713590T3 (pl) * 2017-11-24 2025-09-15 Defensin Therapeutics Aps Ludzka beta 2 defensyna do stosowania w zapobieganiu i leczeniu choroby przeszczep przeciwko gospodarzowi
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CN114903973B (zh) * 2022-04-21 2025-08-29 上海市肺科医院 一种呼吸道粘膜免疫增强药物组合物
US20240252558A1 (en) * 2023-01-29 2024-08-01 The University Of Chicago Probiotics to rescue maternal immune activation-induced neurodevelopment deficits
CN116868958A (zh) * 2023-09-06 2023-10-13 中国人民解放军军事科学院军事医学研究院 构建缺氧导致肠道应激损伤的动物模型的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CA2502324A1 (en) * 2002-10-14 2004-04-29 Lars Thim Glucagon - like peptide - 2 variants
JP2007063219A (ja) * 2005-09-01 2007-03-15 Juntendo 新生児壊死性腸炎疾患予防剤
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
SG172709A1 (en) * 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
US20110223137A1 (en) * 2008-12-05 2011-09-15 Nestec S.A. Compositions for use in low-birth weight infants
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
JP6219277B2 (ja) * 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
EA201200416A1 (ru) * 2012-03-12 2013-09-30 Аделя Сабир кызы Гаджиева Способ ранней диагностики и лечения некротического энтероколита у новорожденных
SG11201406628RA (en) * 2012-04-23 2014-11-27 Chiesi Farma Spa Method and system for the administration of a pulmonary surfactant by atomization
EP2968073B1 (en) * 2013-03-13 2017-08-16 Rush University Medical Center Delivery device for oropharyngeal administration of mother's colostrum and milk
BR112018015170A2 (pt) * 2016-01-26 2018-12-18 Defensin Therapeutics Aps métodos para tratamento de doenças, para promoção de crescimento magro, para tratamento ou normalização de uma microbiota disbiótica no intestino, para aumentar riqueza gênica da microbiota intestinal, para aumentar número de filos da microbiota intestinal, para aumentar produção de ácidos graxos de cadeia curta da microbiota intestinal/metaboloma, para aumentar número de bactérias, para diminuir número de bactérias, defensina a, defensina ss, ou um fragmento bioativo das mesmas, e, defensina a e/ou defensina ss e/ou um glp-1/análogo de glp-1.
MX2019006848A (es) * 2016-12-13 2019-10-07 Defensin Therapeutics Aps Metodos para tratar condiciones inflamatorias de los pulmones.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240150943A (ko) 2023-04-10 2024-10-17 (주)인트젠 영유아용 유산균 프로바이오틱스 조성물

Also Published As

Publication number Publication date
CN111556759A (zh) 2020-08-18
BR112020009254A2 (pt) 2020-10-27
JP2021502363A (ja) 2021-01-28
MX2020004863A (es) 2020-10-14
US20250009844A1 (en) 2025-01-09
WO2019092201A3 (en) 2019-06-27
ZA202002992B (en) 2021-10-27
RU2020115758A (ru) 2021-12-10
CA3082288A1 (en) 2019-05-16
SG11202003868UA (en) 2020-05-28
US20200316172A1 (en) 2020-10-08
EP3706773A2 (en) 2020-09-16
WO2019092201A2 (en) 2019-05-16
AU2018363783A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
US20250009844A1 (en) Maturation of mucosal defense and gut/lung function in the preterm infant
Wright Immunoregulatory functions of surfactant proteins
US20230067261A1 (en) Methods for treating inflammatory conditions of the lungs
Kishore et al. Surfactant proteins SP-A and SP-D in human health and disease
CN112004549B (zh) 用于保护氧敏感革兰氏阳性菌的REG3α
JP2002515893A (ja) ヒトラクトフェリンおよびその改変体の有用な特性
ES2256070T3 (es) Actividad antimicrobiana de la primera agrupacion cationica de lactoferrina humana.
JP7423523B2 (ja) ディフェンシンによる移植片対宿主病の予防と治療
JP5048678B2 (ja) 肺感染症および敗血症を防止および処置するための表面活性タンパク質−ｄ
JP2002530083A (ja) 感染におけるリゾチーム融合タンパク質
US7060677B1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
Dybvig et al. Biological roles of host defense peptides: lessons from transgenic animals and bioengineered tissues

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200528

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211109

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240618

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250103

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D